Abstract
The renoprotection of erythropoietin (EPO) and its derivatives such as helix B surface peptide (HBSP) have attracted a great deal of attention from scientists and clinicians alike. The evolutional achievement in the dissociation of tissue protection and erythropoiesis is obtained through HBSP characterisation and synthesis. We performed a series of studies using EPO, as well as HBSP, in a variety of biological models subjected to transplant-related renal injuries such as ischemia reperfusion injury (IRI) and/or immunosuppressant nephrotoxicity. In this short review, we would like to address the effects of EPO in different formats, and its underlying mechanisms with focuses on apoptosis and inflammation in in vitro, ex vivo and in vivo renal injury models, and to further explore potential applications and challenges in humans.
Keywords: Erythropoietin, helix B surface peptide, ischemia reperfusion injury, inflammation, apoptosis and oxidation.
Current Protein & Peptide Science
Title:Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries
Volume: 18 Issue: 12
Author(s): Yufang Zhang, Weiwei Chen, Yuanyuan Wu and Bin Yang*
Affiliation:
- Renal Group, Department of Infection, Immunity and Inflammation, Maruice Shock Medical Sciences Building, University Road, Leicester LE1 7RH,United Kingdom
Keywords: Erythropoietin, helix B surface peptide, ischemia reperfusion injury, inflammation, apoptosis and oxidation.
Abstract: The renoprotection of erythropoietin (EPO) and its derivatives such as helix B surface peptide (HBSP) have attracted a great deal of attention from scientists and clinicians alike. The evolutional achievement in the dissociation of tissue protection and erythropoiesis is obtained through HBSP characterisation and synthesis. We performed a series of studies using EPO, as well as HBSP, in a variety of biological models subjected to transplant-related renal injuries such as ischemia reperfusion injury (IRI) and/or immunosuppressant nephrotoxicity. In this short review, we would like to address the effects of EPO in different formats, and its underlying mechanisms with focuses on apoptosis and inflammation in in vitro, ex vivo and in vivo renal injury models, and to further explore potential applications and challenges in humans.
Export Options
About this article
Cite this article as:
Zhang Yufang, Chen Weiwei, Wu Yuanyuan and Yang Bin*, Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries, Current Protein & Peptide Science 2017; 18 (12) . https://dx.doi.org/10.2174/1389203717666160909144436
DOI https://dx.doi.org/10.2174/1389203717666160909144436 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Adult Stem Cells and Biocompatible Scaffolds as Smart Drug Delivery Tools for Cardiac Tissue Repair
Current Medicinal Chemistry Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells
Protein & Peptide Letters Cyclophilin D as a Drug Target
Current Medicinal Chemistry Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Distribution, Metabolism, Excretion and Toxicokinetics of Vitexin in Rats and Dogs
Current Pharmaceutical Analysis